Top Ten most popular articles on Pharmafile.com this week
pharmafile | October 20, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â top tenÂ
Another week gone, and it’s deadline day here at Pharmafocus, meaning you can look forward to our November issue next week. Among the headlines on our website this week was the remarkable news that a new AI platform developed at MIT can predict the risk of breast cancer in patients with up to 97% accuracy.
Also, hot on the heels of the FDA’s first-ever approval of a CAR T treatment, Novartis’s Kymriah, the biggest news this week was the US regulator’s authorisation of Gilead’s Yescarta, paving a promising future for the revolutionary cancer therapy.
But far and away the most popular story this week was AstraZeneca’s admission that the early-stage data which proved the efficacy of its acquired dsrug acalabrutinib was actually fabricated by an individual working for the firm that originally develoepd it.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Sanofi plans summit to tackle diabetes in 5 million Nigerian citizens
Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million of the nation’s citizens currently live with the condition.
9. Asking the right questions: Measuring the impact of pharmacovigilance
Are our pharmacovigilance measures as effective as we think? And why is it important to answer that question, especially now? Matt Fellows investigates the projects underway to ensure we’re headed in the right direction.
8. J&J’s third quarter: The good and the bad
It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be broken down into two areas: in the short-term, good, and in the long-term, not so much.
7. Novartis sheds generics plant and 450 jobs amid pricing pressure
Novartis has announced its intention to shut down its US generics manufacturing plant in Broomfield, Colorado, a move that will lead to a loss of 450 jobs over a two-year period.
6. Allergan’s patent shield – The (Native) American dream?
In an unprecedented move, leading global pharmaceutical company Allergan appears to have handed its Orange Book-listed US patents covering its blockbuster dry eye drug Restasis to the Native American St. Regis Mohawk Tribe in Northern New York.
5. Breakthrough AI able to identify 97% of breast cancer risk
Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that is able diagnose patients with breast cancer 97% of the time.
4. First-ever study in the personalised treatment of rare cancers brings promising results
The first-ever trial to treat patients for rare cancers in a personalised manner based on the characteristics of their individual disease has wrought promising results, it has emerged.
3. Gilead gets FDA nod for revolutionary blood cancer treatment
Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s approval for the CAR-T therapy, Yescarta, to become only the second treatment on the market.
2. Breakthrough study could revolutionise MS treatment
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by multiple sclerosis (MS) and, to add to the news, is achieved through the use of a generic allergy medication.
1. AstraZeneca admits cancer data for acquired drug was fabricated
AstraZeneca has revealed that early-stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
